

Information for Connecticut Prescribers of Prescription Drugs

Rezvoglar® (insulin glargine-aglr)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
Rezvoglar®	insulin glargine-aglr	100 units/mL	KwikPen®, 3mL	5	0002-8980-05	\$92.00

Rezvoglar® and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

¹ Source: AnalySource®. Accessed on 04/01/2023. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2023. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.